Iovance Biotherapeutics, Inc. (IOVA)

7.98 -0.15 (-1.85%) At close: 04:00PM EST

Iovance Biotherapeutics, Inc.

825 Industrial Road
Suite 400
San Carlos, CA 94070
United States
650 260 7120
https://www.iovance.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 319

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Frederick G. Vogt Esq., J.D., Ph.D.	Interim CEO, Pres, Gen. Counsel & Corp. Sec.	752.81k	N/A	1974
Mr. Jean-Marc Bellemin M.B.A.	Chief Financial Officer & Principal Accounting Officer	623.6k	N/A	1972
Dr. Igor P. Bilinsky	Chief Operating Officer	577.35k	N/A	1973
Dr. Friedrich Graf Finckenstein M.D.	Chief Medical Officer	649.13k	N/A	1967
Ms. Sara Pellegrino	VP of Investor Relations & PR	N/A	N/A	N/A
Ms. Tracy Winton	Sr. VP of HR	N/A	N/A	N/A
Mr. Howard B. Johnson M.B.A.	Chief Bus. Officer	N/A	N/A	1960
Mr. James Ziegler M.B.A.	Exec. VP of Commercial	N/A	N/A	N/A
Dr. Raj K. Puri M.D., Ph.D.	Exec. VP of Regulatory Strategy & Translational Medicine	N/A	N/A	N/A
Mr. Brian Shew M.B.A.	Sr. VP & Head of Digital and Information Technology	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Corporate governance

Iovance Biotherapeutics, Inc.’s ISS governance QualityScore as of 1 February 2023 is 7. The pillar scores are Audit: 6; Board: 9; Shareholder rights: 3; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.